They decided to try to be a pharma company instead of a diagnostics company. The microarray tech was obsolete, but they did have a lot of data. The problem is that being a pharmaceutical company is very difficult. I always question why they wanted to play in early pipeline rather than using their data to have an edge in later stage acquisitions. Perhaps they felt that running later stages of development and commercialization was too difficult, risky, and capital intensive; but if so then they probably had no business trying to sell drugs in the first place.